HRP20160235T1 - A composition comprising an antibiotic and a dispersant - Google Patents

A composition comprising an antibiotic and a dispersant Download PDF

Info

Publication number
HRP20160235T1
HRP20160235T1 HRP20160235TT HRP20160235T HRP20160235T1 HR P20160235 T1 HRP20160235 T1 HR P20160235T1 HR P20160235T T HRP20160235T T HR P20160235TT HR P20160235 T HRP20160235 T HR P20160235T HR P20160235 T1 HRP20160235 T1 HR P20160235T1
Authority
HR
Croatia
Prior art keywords
product
infections
spp
infection
use according
Prior art date
Application number
HRP20160235TT
Other languages
Croatian (hr)
Inventor
Deborah O'neil
Cedric Charrier
Original Assignee
Novabiotics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Limited filed Critical Novabiotics Limited
Publication of HRP20160235T1 publication Critical patent/HRP20160235T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (14)

1. Produkt koji sadrži sinergistički učinkovitu količinu antibiotskog sredstva i drugog sredstva koje je disperzant, naznačen time da je antibiotik tobramicin, kolistin, gentamicin ili ciprofloksacin i gdje je drugo sredstvo cisteamin.1. A product containing a synergistically effective amount of an antibiotic agent and another agent that is a dispersant, indicated that the antibiotic is tobramycin, colistin, gentamicin or ciprofloxacin and where the other agent is cysteamine. 2. Produkt prema zahtjevu 1 za uporabu kao lijek.2. Product according to claim 1 for use as medicine. 3. Supstrat na koji se produkt prema zahtjevu 1, aplicira ili veže.3. The substrate to which the product according to claim 1 is applied or attached. 4. Supstrat prema zahtjevu 3, naznačen time da je supstrat izabran iz skupine koja se sastoji od zavoja, medicinskih uređaja i trajnih uređaja.4. The substrate according to claim 3, characterized in that the substrate is selected from the group consisting of bandages, medical devices and permanent devices. 5. Supstrat prema zahtjevu 4, naznačen time da je trajni uređaj izabran iz skupine koja se sastoji od stentova, katetera, peritonealnih cijevi za dijalizu, uređaja za drenažu, zglobnih proteza i zubnih implantata.5. The substrate according to claim 4, characterized in that the permanent device is selected from the group consisting of stents, catheters, peritoneal dialysis tubes, drainage devices, joint prostheses and dental implants. 6. Farmaceutski pripravak koji sadrži produkt prema zahtjevu 1 i jedno ili više farmaceutski prihvatljivih otapala, pomoćnih tvari i / ili nosača.6. Pharmaceutical preparation containing the product according to claim 1 and one or more pharmaceutically acceptable solvents, excipients and/or carriers. 7. Produkt prema zahtjevu 1 za uporabu u liječenju ili prevenciji mikrobne infekcije ili bolesti ili stanja povezanih s time.7. A product according to claim 1 for use in the treatment or prevention of a microbial infection or disease or condition related thereto. 8. Produkt za uporabu prema zahtjevu 7, naznačen time da je infekcija, ili bolest ili stanje s time povezano odabrano iz skupine koja se sastoji od infekcija kože ili rana, infekcija srednjeg uha, infekcija gastrointestinalnog trakta, infekcija peritonealne membrane, infekcija urogenitalnog trakta, oralnih infekcija mekog tkiva, formiranja zubnog plaka, infekcija oka, endokarditisa, infekcija kod cistične fibroze, i infekcija trajnih medicinskih uređaja.8. The product for use according to claim 7, characterized in that the infection, or disease or condition associated therewith is selected from the group consisting of skin or wound infections, middle ear infections, gastrointestinal tract infections, peritoneal membrane infections, urogenital tract infections, oral soft tissue infections, dental plaque formation, eye infections, endocarditis, cystic fibrosis infections, and infections of permanent medical devices. 9. Produkt za uporabu prema bilo kojem od zahtjeva 7 i 8, naznačen time da je infekcija mukolitičkog okoliša.9. Product for use according to any one of claims 7 and 8, characterized in that the infection is a mucolytic environment. 10. Produkt za uporabu prema zahtjevu 9, naznačen time da je infekcija bakterijska infekcija povezana s cističnom fibrozom.10. Product for use according to claim 9, characterized in that the infection is a bacterial infection associated with cystic fibrosis. 11. Produkt za uporabu prema bilo kojem od zahtjeva 7 do 10, naznačen time da je infekcija uzrokovana bakterijom izabranom iz skupine koju čine bakterije Pseudomonas spp., Staphylococcus spp., Haemophilus spp., Burkholderia spp., Streptococcus spp. i Propionibacterium spp.11. Product for use according to any one of claims 7 to 10, characterized in that the infection is caused by a bacterium selected from the group consisting of Pseudomonas spp., Staphylococcus spp., Haemophilus spp., Burkholderia spp., Streptococcus spp. and Propionibacterium spp. 12. Produkt za uporabu prema zahtjevu 11, naznačen time da je bakterija Pseudomonas spp.12. Product for use according to claim 11, characterized in that the bacterium Pseudomonas spp. 13. Produkt za uporabu prema zahtjevu 11, naznačen time da je bakterija Burkholderia spp.13. Product for use according to claim 11, characterized in that the bacterium Burkholderia spp. 14. Produkt za uporabu prema zahtjevu 11, naznačen time da je bakterija Staphylococcus spp.14. Product for use according to claim 11, characterized in that the bacterium Staphylococcus spp.
HRP20160235TT 2010-12-14 2016-03-07 A composition comprising an antibiotic and a dispersant HRP20160235T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42300010P 2010-12-14 2010-12-14
GBGB1021186.0A GB201021186D0 (en) 2010-12-14 2010-12-14 Composition
PCT/GB2011/001721 WO2012080700A1 (en) 2010-12-14 2011-12-14 A composition comprising an antibiotic and a dispersant or an anti -adhesive agent
EP11808253.6A EP2651419B1 (en) 2010-12-14 2011-12-14 A composition comprising an antibiotic and a dispersant

Publications (1)

Publication Number Publication Date
HRP20160235T1 true HRP20160235T1 (en) 2016-05-20

Family

ID=43567164

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160235TT HRP20160235T1 (en) 2010-12-14 2016-03-07 A composition comprising an antibiotic and a dispersant
HRP20210280TT HRP20210280T1 (en) 2010-12-14 2021-02-18 A composition comprising a non-peptide antibiotic and cysteamine

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210280TT HRP20210280T1 (en) 2010-12-14 2021-02-18 A composition comprising a non-peptide antibiotic and cysteamine

Country Status (28)

Country Link
US (3) US9782423B2 (en)
EP (2) EP2651419B1 (en)
JP (2) JP5964854B2 (en)
KR (1) KR101955636B1 (en)
CN (1) CN103732232B (en)
AU (3) AU2011343012C1 (en)
BR (2) BR112013015010B1 (en)
CA (1) CA2821032C (en)
CY (2) CY1117447T1 (en)
DK (2) DK2651419T3 (en)
ES (2) ES2565564T3 (en)
GB (1) GB201021186D0 (en)
HK (2) HK1185015A1 (en)
HR (2) HRP20160235T1 (en)
HU (2) HUE027207T2 (en)
IL (2) IL226879B (en)
LT (1) LT3040076T (en)
MX (1) MX346664B (en)
NZ (1) NZ613076A (en)
PL (2) PL3040076T3 (en)
PT (1) PT3040076T (en)
RS (2) RS61469B1 (en)
RU (2) RU2607660C2 (en)
SG (3) SG10201703290UA (en)
SI (2) SI2651419T1 (en)
SM (1) SMT201600121B (en)
UA (1) UA114470C2 (en)
WO (1) WO2012080700A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (en) 2007-05-14 2015-06-17 纽约州立大学研究基金会 Induction of a physiological dispersion response in bacterial cells in a biofilm
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
PT106094A (en) 2012-01-13 2013-07-15 Hovione Farmaciencia S A ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE
WO2014052848A1 (en) * 2012-09-28 2014-04-03 The Regents Of The University Of Michigan Apyrase treatments
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
MX2018013276A (en) 2016-05-26 2019-03-28 Kimberly Clark Co Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface.
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
HRP20230369T1 (en) * 2016-12-15 2023-06-23 Zambon S.P.A. N-acetylcysteine for use as antibacterial agent
EP3366284A1 (en) * 2017-02-27 2018-08-29 Zambon S.p.A. Association of n-acetylcysteine and colistin for use in bacterial infections
JP2020513041A (en) 2017-04-10 2020-04-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Compounds, compositions and methods for pathogen inhibition and / or mucus modification
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020079186A1 (en) * 2018-10-17 2020-04-23 Novabiotics Limited Dosage regime
US20220265583A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN111053696B (en) * 2019-11-19 2022-11-04 温州医科大学附属口腔医院 Super-hydrophobic gel nano-coating for inhibiting bacterial adhesion and preparation method thereof
CN113018443B (en) * 2019-12-27 2022-09-13 海南斯达制药有限公司 Pharmaceutical composition for treating respiratory system diseases and preparation method thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (en) 1974-05-02 1982-01-11 Istituto Chemioterapico PYRIMIDINE DERIVATIVES AND RELATED COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (en) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantable dosing device
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IT1178869B (en) 1984-03-07 1987-09-16 Cagliero Germano PRODUCT TO PREVENT AND FIGHT FOOD TOXICOSIS DUE TO MYCOTOXINS
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
CA2145093C (en) 1992-09-25 2007-04-10 Lawrence Leroy Kunz Therapeutic inhibitor of vascular smooth muscle cells
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
JP3749279B2 (en) 1995-03-01 2006-02-22 日産化学工業株式会社 Antifungal agent for nails
US5624704A (en) * 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6086921A (en) 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000033895A1 (en) 1998-12-07 2000-06-15 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
UA80393C2 (en) 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
ITMI20021881A1 (en) 2002-09-04 2004-03-05 Zambon Spa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS FROM URINARY PATHOGENS.
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN101897970A (en) 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 The compositions and the method that are used for the treatment of diabetes
CA2974538A1 (en) 2004-08-18 2006-02-23 Novabiotics Limited Antimicrobial peptides comprising an arginine-and/or lysine-containing motif
WO2007050565A2 (en) * 2005-10-25 2007-05-03 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
AR057623A1 (en) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd MATERIALS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
ZA200805191B (en) 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
DE102006010642A1 (en) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Drug formulations containing fluoroquinolones
US20080035141A1 (en) * 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
MX2009005783A (en) * 2006-12-01 2009-10-28 Laclede Inc Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears.
US20080131500A1 (en) * 2006-12-04 2008-06-05 The Board Of Regents Of The University Of Texas System Methods and compositions for rapid inactivation of proteins
WO2008092262A1 (en) 2007-01-31 2008-08-07 The Royal Institution For The Advancement Of Learning/Mcgill University Methods and compounds for treatment, prevention and diagnosis of parasitic infection and disease
GB0702021D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US9395352B2 (en) 2007-04-06 2016-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Devices and methods for target molecule characterization
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
RU2371447C2 (en) * 2007-10-05 2009-10-27 Общество С Ограниченной Ответственностью "Саентифик Фьючер Менеджмент" Antibiotic conjugate and antibacterial medicinal agent based on said conjugate
WO2009076722A1 (en) 2007-12-19 2009-06-25 The University Of Melbourne Method of protecting a surface from biological fouling
BRPI0821985A2 (en) * 2008-01-10 2015-06-23 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation having controlled active substance release
BRPI0907561A2 (en) 2008-02-17 2015-08-04 Walcom Animal Science I P 3 Ltd Shrimp Health Improvement Materials and Methods
JP5674684B2 (en) * 2009-02-03 2015-02-25 マイクロビオン コーポレーション Bismuth-thiol as a disinfectant for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
US8815942B2 (en) * 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
WO2013103780A1 (en) 2012-01-06 2013-07-11 Trustees Of Boston University Compositions and methods to boost endogenous ros production from bacteria
US20160106689A1 (en) 2014-09-22 2016-04-21 Novabiotics Limited Use

Also Published As

Publication number Publication date
BR112013015010A2 (en) 2016-08-09
RU2016151115A (en) 2018-11-14
HUE053813T2 (en) 2021-07-28
DK2651419T3 (en) 2016-03-21
MX2013006873A (en) 2013-07-05
SMT201600121B (en) 2016-07-01
EP2651419B1 (en) 2016-02-10
PL2651419T3 (en) 2016-08-31
JP2016196495A (en) 2016-11-24
AU2018282257A1 (en) 2019-01-17
RU2607660C2 (en) 2017-01-10
DK3040076T3 (en) 2021-02-22
HK1220911A1 (en) 2017-05-19
CN103732232B (en) 2016-11-09
US9782423B2 (en) 2017-10-10
IL276342A (en) 2020-09-30
JP5964854B2 (en) 2016-08-03
US20160158169A1 (en) 2016-06-09
PL3040076T3 (en) 2021-06-14
RS61469B1 (en) 2021-03-31
EP2651419A1 (en) 2013-10-23
SG10201703290UA (en) 2017-06-29
CA2821032C (en) 2022-04-12
RS54815B1 (en) 2016-10-31
CY1123951T1 (en) 2022-05-27
AU2011343012A1 (en) 2013-08-01
JP6483058B2 (en) 2019-03-13
EP3040076B1 (en) 2020-12-09
CN103732232A (en) 2014-04-16
US20140357592A1 (en) 2014-12-04
SG10201510095YA (en) 2016-01-28
KR20140029372A (en) 2014-03-10
BR112013015010B1 (en) 2021-01-05
BR122019015601B1 (en) 2021-02-02
RU2016151115A3 (en) 2020-06-18
HK1185015A1 (en) 2014-02-07
WO2012080700A1 (en) 2012-06-21
MX346664B (en) 2017-03-27
CY1117447T1 (en) 2017-04-26
ES2565564T3 (en) 2016-04-05
NZ613076A (en) 2014-12-24
AU2011343012C1 (en) 2017-04-20
RU2013131391A (en) 2015-01-20
AU2011343012B2 (en) 2017-02-02
AU2017201670B2 (en) 2018-12-20
AU2017201670A1 (en) 2017-03-30
ES2856831T3 (en) 2021-09-28
CA2821032A1 (en) 2012-06-21
RU2739249C2 (en) 2020-12-22
UA114470C2 (en) 2017-06-26
SI2651419T1 (en) 2016-06-30
HRP20210280T1 (en) 2021-04-02
GB201021186D0 (en) 2011-01-26
US20120328671A1 (en) 2012-12-27
LT3040076T (en) 2021-03-25
SG191146A1 (en) 2013-07-31
US11020414B2 (en) 2021-06-01
HUE027207T2 (en) 2016-10-28
PT3040076T (en) 2021-02-25
KR101955636B1 (en) 2019-03-08
IL226879B (en) 2020-08-31
JP2013545794A (en) 2013-12-26
EP3040076A1 (en) 2016-07-06
SI3040076T1 (en) 2021-04-30
US9364491B2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
HRP20160235T1 (en) A composition comprising an antibiotic and a dispersant
El-Feky et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces
Dinicola et al. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review.
Campoccia et al. A review of the clinical implications of anti-infective biomaterials and infection-resistant surfaces
JP2012522037A5 (en)
Marcinkiewicz et al. Antibiotic resistance: a" dark side" of biofilm‑associated chronic infections
JP5642929B2 (en) Method for reducing minute biological contamination
Holinka et al. Effects of selenium coating of orthopaedic implant surfaces on bacterial adherence and osteoblastic cell growth
Meije et al. Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection
GB2554629A (en) Prevention and treatment of microbial infections
JP2019104757A (en) Use of seaprose for removing bacterial biofilm
JP2018500387A5 (en)
ES2765348T3 (en) Chitosan Stent Paste
US20220175673A1 (en) Surgical device
JP2015512386A5 (en)
JP2013508269A5 (en)
Amalaradjou et al. Role of bacterial biofilms in catheter-associated urinary tract infections (CAUTI) and strategies for their control
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
Fujimura et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices
Ehrlich et al. Role for biofilms in infectious disease
JP2017514895A5 (en)
WO2016080158A1 (en) Biological film preparation for promoting wound healing and coating and protecting biological organs
JP2023017847A (en) Liposome inhibiting biofilm formation
Subbiahdoss et al. Bridging the gap between in vitro and in vivo evaluation of biomaterial-associated infections
KR20190077433A (en) Materials and methods for inhibiting biofilm